Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.
View Top Employees from Medicenna Therapeutics Corp.Website | http://www.medicenna.com |
Ticker | TSX:MDNA |
Revenue | $15 million |
Funding | $798000 |
Employees | 22 (19 on RocketReach) |
Founded | 2012 |
Address | 2 Bloor St W Fl 7, Toronto, Ontario M4W 3E2, CA |
Phone | (416) 648-5555 |
Technologies |
JavaScript,
HTML,
PHP
+28 more
(view full list)
|
Industry | Biotechnology Research, Healthcare Software, Health Care, Software Development & Design, Medical, Software, Therapeutics |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 541714 Companies |
Looking for a particular Medicenna Therapeutics Corp. employee's phone or email?
The Medicenna Therapeutics Corp. annual revenue was $15 million in 2024.
Bradford Brinton is the Director of Corporate Development of Medicenna Therapeutics Corp..
19 people are employed at Medicenna Therapeutics Corp..
Medicenna Therapeutics Corp. is based in Toronto, Ontario.
The NAICS codes for Medicenna Therapeutics Corp. are [5417, 54, 541, 54171, 541714].
The SIC codes for Medicenna Therapeutics Corp. are [873, 87].